Zamanian M

References (3)

Title : The Protective Roles and Molecular Mechanisms of Troxerutin (vitamin P4) for Treatment of Chronic Diseases: A Mechanistic Review - Zamanian_2020_Curr.Neuropharmacol__
Author(s) : Zamanian M , Bazmandegan G , Sureda A , Sobarzo-Sanchez E , Yousefi-Manesh H , Shirooie S
Ref : Curr Neuropharmacol , : , 2020
Abstract : Troxerutin (TRX), a semi-synthetic bioflavonoid derived from rutin, has been reported to exert several pharmacological effects including antioxidant, anti-inflammatory, antihyperlipidemic, and nephroprotective. However, the related molecular details and its mechanisms remain poorly understood. In the present review, we presented evidences from the diversity in vitro and in vivo studies on the therapeutic potential of TRX against neurodegenerative, diabetes, cancer and cardiovascular diseases with the purpose to find molecular pathways related to the treatment efficacy. TRX has a beneficial role in many diseases through multiple mechanisms including, increasing antioxidant enzymes and reducing oxidative damage, decreasing in proapoptotic proteins (APAF-1, BAX, caspases-9 and-3) and increasing the antiapoptotic BCL-2, increasing nuclear translocation of nuclear factor erythroid 2-related factor 2 (Nrf2) and downregulating the nuclear factor kappaB (NFkappa). TRX also reduces acetylcholinesterase activity and upregulates phosphoinositide 3-kinase/Akt signaling pathway in Alzheimer's disease models. Natural products such as TRX may develop numerous and intracellular pathways at several steps in the treatment of many diseases. Molecular mechanisms of action are revealing novel, possible combinational beneficial approaches to treat multiple pathological conditions.
ESTHER : Zamanian_2020_Curr.Neuropharmacol__
PubMedSearch : Zamanian_2020_Curr.Neuropharmacol__
PubMedID: 32386493

Title : The genomes of four tapeworm species reveal adaptations to parasitism - Tsai_2013_Nature_496_57
Author(s) : Tsai IJ , Zarowiecki M , Holroyd N , Garciarrubio A , Sanchez-Flores A , Brooks KL , Tracey A , Bobes RJ , Fragoso G , Sciutto E , Aslett M , Beasley H , Bennett HM , Cai J , Camicia F , Clark R , Cucher M , De Silva N , Day TA , Deplazes P , Estrada K , Fernandez C , Holland PW , Hou J , Hu S , Huckvale T , Hung SS , Kamenetzky L , Keane JA , Kiss F , Koziol U , Lambert O , Liu K , Luo X , Luo Y , Macchiaroli N , Nichol S , Paps J , Parkinson J , Pouchkina-Stantcheva N , Riddiford N , Rosenzvit M , Salinas G , Wasmuth JD , Zamanian M , Zheng Y , Cai X , Soberon X , Olson PD , Laclette JP , Brehm K , Berriman M
Ref : Nature , 496 :57 , 2013
Abstract : Tapeworms (Cestoda) cause neglected diseases that can be fatal and are difficult to treat, owing to inefficient drugs. Here we present an analysis of tapeworm genome sequences using the human-infective species Echinococcus multilocularis, E. granulosus, Taenia solium and the laboratory model Hymenolepis microstoma as examples. The 115- to 141-megabase genomes offer insights into the evolution of parasitism. Synteny is maintained with distantly related blood flukes but we find extreme losses of genes and pathways that are ubiquitous in other animals, including 34 homeobox families and several determinants of stem cell fate. Tapeworms have specialized detoxification pathways, metabolism that is finely tuned to rely on nutrients scavenged from their hosts, and species-specific expansions of non-canonical heat shock proteins and families of known antigens. We identify new potential drug targets, including some on which existing pharmaceuticals may act. The genomes provide a rich resource to underpin the development of urgently needed treatments and control.
ESTHER : Tsai_2013_Nature_496_57
PubMedSearch : Tsai_2013_Nature_496_57
PubMedID: 23485966
Gene_locus related to this paper: echgr-k4epc5 , hymmi-a0a068x9f5 , echmu-u6hbw4 , echgr-w6ugl0 , echmu-u6hr32 , echmu-a0a068y5f4 , hymmi-a0a068xag4 , hymmi-a0a068x810 , hymmi-a0a068xcc1 , echmu-a0a068yf54 , echgr-a0a068wxj3 , echgr-a0a068wgw1 , hymmi-a0a068xge7 , hymmi-a0a068x8h9 , echmu-a0a068y747 , hymmi-a0a068xgj7 , echgr-a0a068wl60

Title : The genome of the blood fluke Schistosoma mansoni - Berriman_2009_Nature_460_352
Author(s) : Berriman M , Haas BJ , LoVerde PT , Wilson RA , Dillon GP , Cerqueira GC , Mashiyama ST , Al-Lazikani B , Andrade LF , Ashton PD , Aslett MA , Bartholomeu DC , Blandin G , Caffrey CR , Coghlan A , Coulson R , Day TA , Delcher A , DeMarco R , Djikeng A , Eyre T , Gamble JA , Ghedin E , Gu Y , Hertz-Fowler C , Hirai H , Hirai Y , Houston R , Ivens A , Johnston DA , Lacerda D , Macedo CD , McVeigh P , Ning Z , Oliveira G , Overington JP , Parkhill J , Pertea M , Pierce RJ , Protasio AV , Quail MA , Rajandream MA , Rogers J , Sajid M , Salzberg SL , Stanke M , Tivey AR , White O , Williams DL , Wortman J , Wu W , Zamanian M , Zerlotini A , Fraser-Liggett CM , Barrell BG , El-Sayed NM
Ref : Nature , 460 :352 , 2009
Abstract : Schistosoma mansoni is responsible for the neglected tropical disease schistosomiasis that affects 210 million people in 76 countries. Here we present analysis of the 363 megabase nuclear genome of the blood fluke. It encodes at least 11,809 genes, with an unusual intron size distribution, and new families of micro-exon genes that undergo frequent alternative splicing. As the first sequenced flatworm, and a representative of the Lophotrochozoa, it offers insights into early events in the evolution of the animals, including the development of a body pattern with bilateral symmetry, and the development of tissues into organs. Our analysis has been informed by the need to find new drug targets. The deficits in lipid metabolism that make schistosomes dependent on the host are revealed, and the identification of membrane receptors, ion channels and more than 300 proteases provide new insights into the biology of the life cycle and new targets. Bioinformatics approaches have identified metabolic chokepoints, and a chemogenomic screen has pinpointed schistosome proteins for which existing drugs may be active. The information generated provides an invaluable resource for the research community to develop much needed new control tools for the treatment and eradication of this important and neglected disease.
ESTHER : Berriman_2009_Nature_460_352
PubMedSearch : Berriman_2009_Nature_460_352
PubMedID: 19606141
Gene_locus related to this paper: schma-ACHE1 , schma-ACHE2 , schma-c4qb79 , schma-c4qmk4 , schma-g4v9h7 , schma-BCHE , schma-g4vmf3